<DOC>
	<DOC>NCT02007655</DOC>
	<brief_summary>The primary objectives of this study are: - To estimate the incidence rate of unexpected adverse events - To characterize the bleeding events and assess risk factors of bleeding - To identify ancillary baseline variables that may also be associated with adverse outcomes</brief_summary>
	<brief_title>Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Patients who are beginning to receive the treatment with this product under the approved indications, dosage, and administration will be included in this study Patients who are receiving Eliquis outside of its approved indication will be excluded from this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cardiovascular</keyword>
</DOC>